logo
The Ngāi Tahu Research Centre Has Entered Into a Strategic Partnership With De-Extinction Company, Colossal Biosciences, and Sir Peter Jackson, to Resurrect the South Island Giant Moa and Other Taonga Species

The Ngāi Tahu Research Centre Has Entered Into a Strategic Partnership With De-Extinction Company, Colossal Biosciences, and Sir Peter Jackson, to Resurrect the South Island Giant Moa and Other Taonga Species

TE WAIPOUNAMU/SOUTH ISLAND, New Zealand--(BUSINESS WIRE)--Jul 8, 2025--
In a historic indigenous-coordinated initiative, the Ngāi Tahu Research Centre has entered into a collaboration with Colossal Biosciences, a Texas-based genetic engineering and de-extinction company, and acclaimed filmmaker Sir Peter Jackson, to work together to resurrect the extinct South Island Giant Moa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708706550/en/
AI rendering of the South Island Giant Moa
The Ngāi Tahu Research Centre was established in 2011 to support the intellectual growth and development of Ngāi Tahu, the principal iwi (Māori tribe) of the southern region of New Zealand. A multi-disciplinary hub based at the University of Canterbury; the Ngāi Tahu Research Centre will direct all aspects of this project. This extends longstanding Ngāi Tahu involvement with species protection and ecological restoration and builds on the Research Centre's strong record of international collaboration.
The partners aim to place Māori values, cultural heritage, and ecological knowledge at the center of de-extinction and species preservation efforts, thereby producing a world-leading model of scientific collaboration with indigenous people. In doing so, Ngai Tahu communities and whānau (families) will have opportunities to help guide this project: from laboratory research to conservation planning and implementation.
This ambitious partnership, which integrates mātauranga Māori (traditional knowledge) with advanced genetic engineering to support ecological restoration and revolutionary conservation tools for taonga (treasured) species, signals a new era of indigenous leadership in scientific innovation. Moreover, the technology will be open sourced and available to anyone who wants to use it for conservation purposes at the direction of the Ngāi Tahu Research Centre.
Colossal Biosciences has committed a large investment to New Zealand to build biotechnology within and protect its unique biological heritage, including flora and fauna found nowhere else on Earth. New Zealand is a biodiversity hotspot due to its isolation and natural history, with a high proportion of endemic species. In the partnership, Colossal:
Colossal scientists recently joined Ngāi Tahu archaeologist Kyle Davis on a visit to caves and other sites known to contain significant moa subfossil deposits within the Ngāi Tahu takiwā. Davis remarked, 'our earliest ancestors in this place lived alongside moa and our records, both archaeological and oral, contain knowledge about these birds and their environs. We relish the prospect of bringing that into dialogue with Colossal's cutting-edge science as part of a bold vision for ecological restoration.'
Director of the Ngāi Tahu Research Centre, Professor Mike Stevens similarly notes that moa harvesting was one of the things that transformed tropical East Polynesian explorers into subtropical South Polynesia Māori. 'During the fourteenth and fifteenth centuries, moa provided meat for sustenance, and bones and feathers for tools and decoration, especially in Te Waipounamu. And the loss of moa, through over-harvesting and habitat modification, was a salutary lesson as to the New Zealand archipelago's 'fragile plenty'.' Stevens further comments that, 'we Ngāi Tahu have successfully partnered with the New Zealand government over many decades to protect and enhance endangered species, especially bird species. However, we are particularly excited by this project because of the extent to which it enables us to exercise our rangatiratanga (leadership) and tikanga (customs) and the potential to bring ecological and economic aspirations into a singular frame. We also see huge importance in this technology as we enter the Anthropocene.'
Collaborating scientist Paul Scofield, Senior Curator Natural History at Canterbury Museum, and an Adjunct Professor in the Department of Earth and Environment at the University of Canterbury says, 'The gigantic moa were a cornerstone of Aotearoa/New Zealand ecosystems. Colossal Biosciences and the Ngāi Tahu Research Centre are providing New Zealand conservationists with an unprecedented opportunity to recreate lost taonga (treasured) moa species. This Ngāi Tahu Research Centre-led initiative will drive new historical, ecological, and scientific discoveries on the path to recreating moa. The knowledge gained will be beneficial to all of New Zealand, to conservation, and the world.' Scofield has over thirty years of experience in conservation and avian palaeobiology in New Zealand, the Antarctic, Arctic, central Pacific and Caribbean and is one of the leading moa researchers and curator of the largest collection of moa bones in the world.
Ben Lamm, CEO and co-founder of Colossal Biosciences, thanked Peter Jackson for bringing all the parties together and expressed enthusiasm about supporting the initiative: 'We are honored to contribute our advanced computational and genetic engineering capabilities under the direction of the Ngāi Tahu Research Centre. This partnership represents a new model where indigenous leadership guides scientific endeavors, recognizing that traditional ecological knowledge and cultural context are essential to responsible de-extinction and species preservation efforts. There is so much knowledge that will be unlocked and shared on the journey to bring back the iconic moa.'
'I'm delighted to partner with the Ngāi Tahu Research Centre and Colossal Biosciences on a mission to save some of our most precious taonga. Resources will be put into ensuring some of the most critically endangered species in Aotearoa/New Zealand are protected for future generations,' said Sir Peter Jackson, the acclaimed filmmaker and proud New Zealander who previously invested in Colossal's de-extinction projects. 'With the recent resurrection of the dire wolf, Colossal has also made real the possibility of bringing back lost species. There's a lot of science still to be done – but we can start looking forward to the day when birds like the moa or the huia are rescued from the darkness of extinction. Exciting times lay ahead! Even the journey will bring incredible insights about the history of this land and enrich discussions as to the potential nature of our future here.'
About the Moa
Moa were flightless birds endemic to New Zealand that went extinct approximately 600 years ago, approximately two centuries after Polynesian settlement. These remarkable birds, which consisted of nine distinct species, ranged from turkey-sized species to the South Island Giant Moa ( Dinornis robustus ) which stood up to 3.6 meters tall with neck outstretched and weighed approximately 230 kilograms.
As large herbivores, moa played crucial ecological roles in New Zealand's forests and grasslands for millions of years. Their browsing habits shaped vegetation structure and composition, while their seed dispersal activities influenced plant distribution patterns. The extinction of moa resulted in significant changes to New Zealand's ecosystems, creating cascading effects still evident today.
Recent research has shown that moa populations were stable until human arrival, with extinction occurring within a century of Polynesian settlement, primarily due to hunting and habitat change. This rapid extinction represents one of the most well-documented examples of human impact on megafauna.
'The first time I flew over New Zealand's South Island, I was captivated by the breathtaking landscapes,' said Robert Nelsen, renowned biotechnology investor and Managing Director of ARCH Venture Partners, who has also provided financial support for the project. 'I remember hearing incredible stories about the moa – these extraordinary giant birds that once roamed these valleys. My immediate thought was simply, 'if the Māori people want them back, we should do everything in our power to support their wishes.' It just felt like one of those projects that needed the right collaboration to make happen. I'm excited to support this ambitious scientific endeavor that connects New Zealand's past with its future.'
The Māori-Directed De-extinction Approach
Dr. Beth Shapiro, Colossal's Chief Science Officer and renowned evolutionary biologist specializing in ancient DNA, emphasized the scientific and ecological value of the Māori-led approach: 'This partnership represents an unprecedented opportunity to combine indigenous ecological knowledge with genomic technology to better understand not just the moa, but the entire ecosystem they inhabited. By studying ancient DNA, we can gain insights into how these keystone species shaped New Zealand's unique biodiversity and apply these lessons to strengthen the resilience of modern ecosystems facing climate change and habitat loss.'
The partnership will follow a deliberate, step-by-step methodology that respects scientific rigor while reflecting Māori values and traditional ecological knowledge. This phased approach begins with expeditions to recover ancient DNA and genomic analysis, followed by gene identification and functional characterization, biological inference from genomic data, and the development of reproductive technologies. Various advancements including deeper comparative genomics across multiple bird families, new PGC culture conditions, interspecies surrogacy, and artificial egg membranes will all advance the next generation conservation toolkits for species preservation of additional taonga (treasured) species. In parallel, the project will incorporate animal husbandry expertise focused on related avian species to better understand developmental requirements and behavioral patterns that would inform any future restoration efforts.
Dr. Anna Keyte, Avian Species Director at Colossal Biosciences, shared her enthusiasm for the collaborative work ahead: 'Working with Ngāi Tahu experts to develop technologies that support moa restoration is an incredible scientific opportunity with profound cultural significance. The avian genomics team is particularly excited to apply our expertise in ways that honor Māori values while advancing conservation science. The technologies we develop together on the path to moa de-extinction will have immediate applications for conservation of existing threatened bird species across Aotearoa/New Zealand.'
Educational and Economic Opportunities
Beyond the scientific and ecological dimensions, the Ngāi Tahu Research Centre, along with the Canterbury Museum, both located in Christchurch, New Zealand, are looking to create sustainable economic opportunities to benefit Ngāi Tahu and the wider Te Waipounamu/South Island community. As part of its contribution to the overall project, the Ngāi Tahu Research Centre will explore how best to develop Ngāi Tahu-owned and operated ecotourism ventures and research facilities that showcase Māori leadership in conservation innovation.
The project will also establish educational programs that critically engage with Ngāi Tahu knowledge systems and offer fresh thinking about their relationship with relevant scientific concepts. These programs will ensure that understandings of the moa, and its potential return to the Ngāi Tahu landscape, are grounded in Māori perspectives. These programs will be developed and delivered by Māori researchers and educators, with a view to creating sustainable employment pathways.
For more information, please visit https://colossal.com/moa/.
ABOUT THE NGĀI TAHU RESEARCH CENTRE
Established in 2011, the multi-disciplinary Ngāi Tahu Research Centre will gather relevant cultural and ecological knowledge pertaining to moa, and the landscapes they once roamed, as part of its offering to this partnership. The Centre's central role in this project will set a new global benchmark for indigenous leadership in scientific innovation and ecological restoration.
ABOUT COLOSSAL BIOSCIENCES
Colossal was founded by emerging technology and software entrepreneur Ben Lamm and world-renowned geneticist and serial biotech entrepreneur George Church, Ph.D., and is the first to apply CRISPR technology for the purposes of species de-extinction. Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies. To follow along, please visit: www.colossal.com.
ABOUT CANTERBURY MUSEUM
Canterbury Museum is the largest museum in Te Waipounamu/the South Island of New Zealand. It holds the largest collection of moa remains in the world. The museum's founder, Sir Julius von Haast, was instrumental in building this collection, often exchanging moa bones with overseas museums to acquire other valuable artifacts and specimens. These exchanges, alongside extensive local excavations, made it the pivotal institution for understanding the biology of these gigantic extinct birds.
Website: https://colossal.com/
YouTube: https://www.youtube.com/@itiscolossal
Instagram: https://www.instagram.com/colossal/
Facebook:https://www.facebook.com/itiscolossal
X:https://x.com/colossal
LinkedIn: https://www.linkedin.com/company/itiscolossal/
TikTok: https://www.tiktok.com/@colossal
View source version on businesswire.com:https://www.businesswire.com/news/home/20250708706550/en/
CONTACT: COLOSSAL PRESS CONTACTS:
R&CPMK /[email protected]
Thinkerbell /[email protected]
KEYWORD: AUSTRALIA/OCEANIA NEW ZEALAND
INDUSTRY KEYWORD: RESEARCH ENVIRONMENT ENTERTAINMENT GENETICS ENVIRONMENTAL HEALTH SUSTAINABILITY BIOTECHNOLOGY CELEBRITY HEALTH SCIENCE
SOURCE: Colossal Biosciences
Copyright Business Wire 2025.
PUB: 07/08/2025 01:00 PM/DISC: 07/08/2025 01:01 PM
http://www.businesswire.com/news/home/20250708706550/en
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elon Musk reveals target date for next Starship launch
Elon Musk reveals target date for next Starship launch

Digital Trends

time31 minutes ago

  • Digital Trends

Elon Musk reveals target date for next Starship launch

Everything went quiet following the dramatic explosion last month that destroyed SpaceX's Starship spacecraft during ground-based preparations for the vehicle's 10th flight test. But SpaceX chief Elon Musk has now revealed that his team expects to fly the Starship — comprising the first-stage Super Heavy booster and the upper-stage Starship spacecraft — in about three weeks' time. Recommended Videos The huge explosion at SpaceX's Starbase facility in Boca Chica, Texas, took everyone by surprise, and fortunately no one was killed or injured in the massive fireball. A few days after it happened, SpaceX said the explosion occurred as the team was loading cryogenic propellant onto the spacecraft in preparation for a six-engine static fire test 'when a sudden energetic event resulted in the complete loss of Starship and damage to the immediate area surrounding the stand.' SpaceX said that its preliminary investigation indicated 'the potential failure of a pressurized tank known as a COPV, or composite overwrapped pressure vessel, containing gaseous nitrogen in Starship's nosecone area,' though it has yet to publish a full data review, which should contain more details about what actually happened. The Starship program is certainly no stranger to large explosions and disintegrations, but they usually occur in midair, well after the rocket has left the launchpad. The first Starship flight test took place in April 2023. During the early part of the ascent, multiple Raptor engines failed on the Super Heavy booster. When stage separation failed to occur, the vehicle began to spin and was intentionally destroyed by the flight termination system about four minutes after launch at an altitude of 24.2 miles (39 km). The following eight flights have produced mixed results — while the team has managed to land the Super Heavy back at base in what is an extraordinary maneuver, the upper-stage spacecraft has suffered some rougher rides in recent flights. Still, SpaceX seems pretty happy with the flight tests overall, and is using the data gathered from each one to try to improve the design and performance of the vehicle. Once fully operational, the Starship will be used for crew and cargo missions to the lunar surface, with crewed missions to Mars also on the cards.

UK government targets manufacturing as it eyes £41bn life science sector growth
UK government targets manufacturing as it eyes £41bn life science sector growth

Yahoo

time7 hours ago

  • Yahoo

UK government targets manufacturing as it eyes £41bn life science sector growth

The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector for the country's economy. In a new Life Sciences sector plan, the government outlined a six-point action plan to ensure the sector reaches its forecasted value increase of £41bn, representing a growth of 165% by 2035. The government is aiming to make the UK the leading life sciences economy in Europe, and third largest in the world behind only America and China. While excelling at research and development (R&D), the report outlines difficulties with commercialisation and adoption. For example, despite being the first country to approve a CRISPR-based medicine, Vertex and CRISPR Therapeutics' Casgevy for sickle cell anaemia is primarily commercialised overseas. In a bid to scale industry, the government has pledged £520m to improve life science manufacturing. Outlaid via the Life Sciences Innovative Manufacturing Fund (LSMIF), the investment will aim to expand the UK's manufacturing capabilities and supply chain security. The initiative comes at a crucial time, as British pharmaceutical companies are significantly increasing their investments in the United States. GSK invested $800m in drug substance and drug product manufacturing facilities in the US in October 2024. AstraZeneca – which has a market cap of £162bn – is reportedly plotting a move of its public listing to the US stock exchange in what would be a major blow to the UK economy. To facilitate the industry's expansion, the government will look to increase access to scale-up capital. There has been a cautious domestic investor base, leading to a lull in emerging companies with high economic outputs. The government will measure investment by the number of UK life science companies with a valuation of over £10bn, the number of companies on the FTSE 300, and the number of initial public offerings (IPOs) in the sector. From a regulatory standpoint, the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute of Care and Excellence (NICE) will be supported to provide faster approvals and more efficient reimbursement. Optimism and criticism for UK life sciences MHRA's chief executive Lawrence Tallon welcomed the news, saying: 'It's great to see the MHRA is recognised as a pivotal partner in delivering the plan's vision - by supporting innovation, protecting public health, and making the UK a global destination for innovators to research, develop and launch cutting-edge medical products.' David Stockdale, chief executive of the British Healthcare Trades Association (BHTA) highlighted the importance of reducing regulatory and financial barriers to accelerate faster delivery of innovative MedTech solutions to patients. "We welcome today's announcement which rightly aims to make the UK a leading hub for investment and innovation in lifesaving MedTech, an essential step if we are to improve patient care and cut down waiting times. We particularly welcome the renewed commitments to the Life Sciences Innovative Manufacturing Fund and the NHS Innovator Passports. Our members are eager to deliver their innovative products and services to patients more quickly and efficiently, and we look forward to working with the Government to make this a reality. Clinical trials are set to benefit from the plan, with a new 150 day or lower target for trial set up times. Finally, up to £600m will be put towards an artificial intelligence (AI)-ready health data platform, a strategy already launched in April 2025. The BioIndustry Association (BIA) said: 'The life science sector plan is right to focus on getting substantially more public and private investment in early-stage companies, improved access to data, trials and skills to help companies grow, and more streamlined regulation and market access pathways to get innovative medicines to NHS patients.' However, the Association of the British Pharmaceutical Industry (ABPI) commented that the plan falls short of investing in innovative medicines. Richard Torbett, Chief Executive of the ABPI, said: [The UK life sciences sector] has been struggling to remain competitive and attractive to investment. The solutions proposed are necessary and important, but they are not enough to turn around the UK's decline. 'The UK must address the core issue holding back the life sciences sector, the long-term disinvestment in innovative medicines that is increasingly preventing NHS patients from accessing medications that are available in other countries.' The life science sector plan comes hot on the heels of the 10-year health plan unveiled for the NHS earlier this month, which placed emphasis on technology and digitalisation. "UK government targets manufacturing as it eyes £41bn life science sector growth" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Prima Mente Launches Pleiades, a Large-Scale Human Whole-Epigenome Foundation Model with Clinical Applications for Alzheimer's Disease
Prima Mente Launches Pleiades, a Large-Scale Human Whole-Epigenome Foundation Model with Clinical Applications for Alzheimer's Disease

Business Wire

time7 hours ago

  • Business Wire

Prima Mente Launches Pleiades, a Large-Scale Human Whole-Epigenome Foundation Model with Clinical Applications for Alzheimer's Disease

LONDON & SAN FRANCISCO--(BUSINESS WIRE)-- Prima Mente today announced the launch of Pleiades, a family of large-scale foundation models created to understand the epigenomic and molecular landscape of human disease. Pleiades represents generative transformers (90M, 600M, and 7B parameters) trained on 1.9 trillion tokens at single-nucleotide resolution. The work is introduced in a newly released preprint, authored in collaboration with researchers from University of Oxford, Hebrew University of Jerusalem, and University of Gothenburg. Trained on a methylation atlas of human cell types as well as cell-free DNA (cfDNA), Pleiades represents a new era in Alzheimer's research and translational medicine – offering the ability to detect disease-relevant signals from blood with unprecedented resolution across cellular subtypes, identify molecular profiles for experimental design, and reveal targets for early intervention. 'We believe epigenetics and cfDNA offer one of the most powerful, underutilized entry points into understanding the brain,' said Ravi Solanki, CEO of Prima Mente. 'They give us a non-invasive lens into cellular activity and dysfunction – particularly in neurodegeneration – at a resolution that was unimaginable just a few years ago. With Pleiades, we're building the AI infrastructure to translate that signal into meaningful discovery, diagnosis, and eventually, intervention.' In contrast to traditional models, Pleiades uses a large-scale transformer-based architecture to learn directly from raw sequencing data. It predicts the cell type of origin of cfDNA fragments, uncovers tissue and disease-specific methylation patterns, and generates synthetic cfDNA to power in silico experimentation. Critically, the team demonstrated that model performance scales reliably with data and compute, extending AI's scaling laws seen in large language and vision models to biology and laying the foundation for future multiomic modeling. The model has so far been applied to a variety of biological tasks, including tissue classification, disease detection, and fragment reconstruction, allowing it to generalize across tissues and diseases while learning shared representations of molecular function. In early Alzheimer's work, Pleiades has shown the ability to detect neuron- and microglia-, and T cell-derived cfDNA signatures that signal neurodegeneration before clinical symptoms appear. 'Pleiades represents an important step forward in how we study Alzheimer's disease using blood-based biomarkers,' said Professor Henrik Zetterberg, a leading researcher in neurodegeneration at the University of Gothenburg. 'Understanding the cell type origin and regulatory disruption at this level could enable earlier, more accurate diagnosis and reveal new biological pathways for intervention. I was thrilled to see the performance of the approach alongside the protein-based biomarkers—so much exciting research can be done and the technology really opens for personalized medicine approaches finding neurodegenerative disease subtypes with varying disease drivers.' Prima Mente has partnered with NVIDIA to scale training across DGX infrastructure, ensuring high-performance compute can be directed toward decoding the biology of complex disease. Additionally, to train and test Pleiades, Prima Mente worked with Nebius, Siam AI, and Eternis Labs for distributed compute infrastructure. The teams will continue to collaborate together on data collection and future training initiatives. Pleiades caps a period of strong momentum for Prima Mente. Alongside the model's release, the company built a wet lab for high-throughput multiomic data generation and has begun modeling disease progression across regulatory, transcriptomic, and proteomic layers. The company is launching a 1,000-patient Alzheimer's study next month and is actively building partnerships across AI, academia, and life sciences to translate these models into tools for discovery, diagnosis, and ultimately, intervention. About Prima Mente Prima Mente is based in San Francisco and London. Its mission is to build intelligent infrastructure to deeply understand the brain, protect it from neurological disease, and enhance it in health.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store